A development-stage biotechnology company focused on therapies for benign prostatic hyperplasia and other age-related conditions. Its primary asset has been NX-1207, an injectable treatment intended as a minimally invasive alternative to surgery for prostate enlargement, which has undergone multiple...
1 member of Congress has disclosed 1 trade in Nymox Pharmaceutical Corporation (NYMX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-22 | Greg Francis Murphy | sell | $50K – $100K |